Yissum - Research Development Company of the Hebrew University

New Nasal Delivery Technology for Quick-Onset Treatment of Insomnia, Erectile Dysfunction, Pain, Hot Flashes and Other Disorders

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Platform technology

OLD: New Nasal Delivery Technology for Quick-Onset Treatment such as Insomnia, Erectile Difunction, Pain, Hot Flashes and Other
Project ID : 6-2009-2237

Description of the technology

CNS (MS, Insomnia, Sleepiness, Emesis, Parkinson), Hyperglycemias,
Hot Flushes, Obesity


Drug delivery, Novel Carrier

Development Stage

Concept has been proved in animal models (including sheep) for manydiseasesand various drugs including large molecules and peptides. Industrial upscale results.

Patent Status

Patents filed in United States, Europe, Japan, Israel, India and China; published in the United States, Europe and Japan


With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs including peptides..


  • Technology for efficient drug therapy by nasal delivery
  • Wide number of experiments in animal models
  • Examples: very efficient treatment and disease prevention in EAE mice (drugs: steroids, glatiramer acetate, new drug combinations), antiemetic in rat model (drug: granisetron),antiwrithing effect (drug: diazepam), malaria prevention and treatment ( drug: DHA), insomnia (drugs: benzodiazepine, melatonin, antihistamines ), obesity (drug: insulin, others) Parkinsonrotational model (drug: apomorphine),

Our Innovation

  • Platform drug delivery carrier technology for approved or new drugs, single drugs or combination of drugs (also including new drug combinations).

Key Features

  • Improved delivery into the brain
  • Better bioavailability by nasal route than by oral or subcutaneous routes
  • Particularly important in crisis management such as for multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycemia, hypoglycaemia, hot flushes, emesis, Parkinson rigidity
  • Carrier ingredients already have FDA approval for nasal delivery
  • Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication

Development Milestones

  • Proof of concept achieved in animal models
  • Planned Phase I and Phase II trials

The Opportunity

  • Seeking investment and cooperation for ongoing development of a number of drugs
  • Prior FDA ingredient approvals will lead to faster product approval process

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Elka Touitou
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • Drug delivery

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.